Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Digoxin vs Beta Blockers for Left Atrium Reservoir Function in Atrial Fibrillation
NCT05540600Phase 3Unknown
- Sponsor
- Université de Monastir
- Start
- Sep 2022
- Primary completion
- Jan 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of digoxin in Atrial fibrillation (AFib) (2 arms), sponsored by Université de Monastir. Primary endpoint: Left atrium reservoir strain at 4 weeks. Status: unknown.
02
Drugs
digoxin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05540600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05540600.